Psychedelic Bulletin #124: MAPS Wraps Second Phase 3 MDMA Trial; Preparing for atai’s PCN-101 Results; Tactogen Launches Community Funding Round

This Week: MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of atai’s PCN-101 Phase 2a Readout Tactogen Launches Community Stakeholder Initiative, Allowing Public to Purchase Equity Psychedelic Drug Developers Take Note: NICE’s Clarification of Spravato Coverage Rejection Might Prove Prophetic and lots more…

Source